SEOM clinical guidelines for the treatment of renal cell carcinoma

Por Bellmunt, J., Puente, J., Garcia de Muro, J., Lainez, N., Rodríguez, C., Duran, I.
Publicado no Clin Transl Oncol (2014)

Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4

Por Said, Rabih, Amato, Robert J.
Publicado em 2013

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Por Derosa, L, Hellmann, M D, Spaziano, M, Halpenny, D, Fidelle, M, Rizvi, H, Long, N, Plodkowski, A J, Arbour, K C, Chaft, J E, Rouche, J A, Zitvogel, L, Zalcman, G, Albiges, L, Escudier, B, Routy, B
Publicado no Ann Oncol (2018)

Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry

Por Wagstaff, J., Jones, R., Hawkins, R., Porfiri, E., Pickering, L., Bahl, A., Brown, J., Buchan, S.
Publicado no Ann Oncol (2016)

Chromosome 3p Loss–Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma

Por Hsieh, James J., Le, Valerie H., Oyama, Toshinao, Ricketts, Christopher J., Ho, Thai Huu, Cheng, Emily H.
Publicado no J Clin Oncol (2018)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer

Por Powles, T., Kayani, I., Blank, C., Chowdhury, S., Horenblas, S., Peters, J., Shamash, J., Sarwar, N., Boletti, K., Sadev, A., O'Brien, T., Berney, D., Beltran, L., Haanen, J., Bex, A.
Publicado em 2011

Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer

Por Amato, Robert J., Stepankiw, Mika
Publicado em 2012

SEOM clinical guideline for treatment of kidney cancer (2017)

Por Gallardo, E., Méndez-Vidal, M. J., Pérez-Gracia, J. L., Sepúlveda-Sánchez, J. M., Campayo, M., Chirivella-González, I., García-del-Muro, X., González-del-Alba, A., Grande, E., Suárez, C.
Publicado no Clin Transl Oncol (2017)

Randomized Study of High - Dose and Low - Dose Inter leukin - 2 in Patients With Metastatic Renal Cancer

Por Yang, James C., Sherry, Richard M., Steinberg, Seth M., Topalian, Suzanne L., Schwartzentruber, Douglas J., Hwu, Patrick, Seipp, Claudia A., Rogers-Freezer, Linda, Morton, Kathleen E., White, Donald E., Liewehr, David J., Merino, Maria J., Rosenberg, Steven A.
Publicado em 2003

Defining Early-Onset Kidney Cancer: Implications for Germline and Somatic Mutation Testing and Clinical Management

Por Shuch, Brian, Vourganti, Srinivas, Ricketts, Christopher J., Middleton, Lindsay, Peterson, James, Merino, Maria J., Metwalli, Adam R., Srinivasan, Ramaprasad, Linehan, W. Marston
Publicado em 2014

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma

Por Hahn, Olwen M., Yang, Cheng, Medved, Milica, Karczmar, Gregory, Kistner, Emily, Karrison, Theodore, Manchen, Elizabeth, Mitchell, Myrosia, Ratain, Mark J., Stadler, Walter M.
Publicado em 2008

Measuring quality care in localized renal cell cancer: use of appropriate preoperative investigations in a population-based cohort

Por Moideen, N., Marzouk, K.H., Matheson, K.J., Wood, L.A.
Publicado no Curr Oncol (2017)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

Por Gotink, Kristy J., Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Dekker, Henk, Poel, Dennis, Azijli, Kaamar, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W.
Publicado no Cell Oncol (Dordr) (2015)

Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation

Por Avilés, A., Neri, N., Huerta–Guzmán, J., Nambo, M.J.
Publicado em 2013

Stereotactic Radiosurgery for Renal Cancer Brain Metastasis: Prognostic Factors and the Role of Whole-Brain Radiation and Surgical Resection

Por Ippen, Franziska M., Mahadevan, Anand, Wong, Eric T., Uhlmann, Erik J., Sengupta, Soma, Kasper, Ekkehard M.
Publicado no J Oncol (2015)

Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma

Por Saigal, CS, Deibert, CM, Lai, J, Schonlau, M
Publicado em 2008

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies

Por Voss, M. H., Bastos, D. A., Karlo, C. A., Ajeti, A., Hakimi, A. A., Feldman, D. R., Hsieh, J. J., Molina, A. M., Patil, S., Motzer, R. J.
Publicado no Ann Oncol (2014)

Characterizing Recurrent and Lethal Small Renal Masses in Clear Cell Renal Cell Carcinoma Using Recurrent Somatic Mutations

Por Manley, Brandon J, Reznik, Ed, Ghanaat, Mazyar, Kashan, Mahyar, Becerra, Maria F, Casuscelli, Jozefina, Tennenbaum, Daniel, Redzematovic, Almedina, Carlo, Maria I., Sato, Yusuke, Arcila, Maria, Voss, Martin H., Feldman, Darren R., Motzer, Robert J., Russo, Paul, Coleman, Jonathan, Hsieh, James J., Hakimi, Ari A.
Publicado no Urol Oncol (2017)

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Por Rini, Brian I., Halabi, Susan, Rosenberg, Jonathan E., Stadler, Walter M., Vaena, Daniel A., Ou, San-San, Archer, Laura, Atkins, James N., Picus, Joel, Czaykowski, Piotr, Dutcher, Janice, Small, Eric J.
Publicado em 2008

Systemic therapy for advanced renal cell carcinoma

Por Larkin, James M.G., Kipps, Emma L.S., Powell, Ceri J., Swanton, Charles
Publicado em 2009